| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DTR; DTS; DTSF; HB-EGF; HBEGF; HEGFL |
| Entrez GeneID | 1839 |
| WB Predicted band size | Calculated MW: 23 kDa; Observed MW: 23 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human HBEGF |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于HBEGF抗体的3篇文献信息及简要摘要：
---
1. **文献名称**：*"Heparin-binding EGF-like growth factor (HB-EGF) is a promising tumor marker for oral squamous cell carcinoma"*
**作者**：Miyamoto S., et al.
**摘要**：该研究揭示了HBEGF在口腔鳞状细胞癌中的过表达现象，并开发了特异性抗体用于检测。实验表明，HBEGF抗体可抑制肿瘤细胞增殖和迁移，提示其作为潜在治疗靶点的价值。
---
2. **文献名称**：*"Specific blockade of heparin-binding EGF-like growth factor signaling attenuates atherosclerotic plaque development"*
**作者**：Kinugasa Y., et al.
**摘要**：通过建立动脉粥样硬化小鼠模型，研究团队使用HBEGF中和抗体阻断其与EGFR的相互作用，显著减少血管炎症和斑块形成，证实HBEGF抗体在心血管疾病中的治疗潜力。
---
3. **文献名称**：*"Targeting HB-EGF in ovarian cancer by a monoclonal antibody suppresses peritoneal dissemination"*
**作者**：Hamaoka T., et al.
**摘要**：该文献报道了一种靶向HBEGF的单克隆抗体，在卵巢癌模型中有效抑制肿瘤腹膜转移，并增强化疗药物敏感性，为联合治疗策略提供了实验依据。
---
这些研究涵盖了HBEGF抗体在肿瘤、心血管疾病等领域的应用机制及治疗效果。如需具体期刊信息或发表年份，可进一步补充检索。
Heparin-Binding EGF-like Growth Factor (HBEGF) is a member of the epidermal growth factor (EGF) family that binds to and activates EGF receptors (EGFR/ERBB1 and HER4/ERBB4). It plays critical roles in cell proliferation, migration, survival, and differentiation. HBEGF is synthesized as a transmembrane precursor protein, which undergoes proteolytic cleavage to release a soluble, biologically active form. This growth factor is involved in physiological processes such as wound healing, tissue repair, and embryonic development, but it also contributes to pathological conditions, including cancer progression, inflammatory diseases, and cardiovascular disorders. In cancer, HBEGF promotes tumor growth, angiogenesis, and metastasis by stimulating EGFR signaling.
HBEGF antibodies are essential tools for detecting and quantifying HBEGF expression in research and diagnostic applications. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and ELISA to study HBEGF's localization, expression levels, and interactions in various tissues or disease models. These antibodies help elucidate HBEGF's dual role in both protective mechanisms (e.g., cardioprotection during ischemia) and harmful pathways (e.g., atherosclerosis or tumorigenesis). Researchers also utilize neutralizing HBEGF antibodies to inhibit its activity, exploring therapeutic potential in cancers or inflammatory diseases. Validated antibodies ensure specificity for distinguishing HBEGF from other EGF family members, aiding precise mechanistic studies and biomarker development.
×
